Keynote Speaker for this Event: Paul F. Skultety, PhD, Director, Pharmaceutical Development Services, Xcelience, LLC

Sponsored by:

Driven by pipeline productivity objectives and financial constraints, pharmaceutical companies of all sizes are under pressure to reach critical milestones faster in spite of challenging molecular properties associated with their candidate, and with limited active pharmaceutical ingredient (API).

The ability to work smarter has become a critical survival skill in order to move drug development candidates forward faster and to maximize the chance for success.

Though not all are relevant for commercial scale, there are a host of formulation development options to consider that enable speed to first-in-human studies while conserving API and other resources. API in bottle, powder in bottle, API into capsule, and traditional formulations are all approaches worthy of consideration as possible formulation options for clinical supplies for a Phase I clinical trial.

This webinar will address considerations for prototype formulation development, formulation options for phase I studies, a prototype formulation approach, strategies to overcome poorly soluble compounds, liquid in capsule, and controlled release formulations.

Access to this archive is given on the understanding that you agree to the provision of your contact information to Xtalks sponsors and partners. Only primary contact information will be shared and this information will only be shared for the purposes of providing relevant offers. This registration form is an application only. Xtalks has the right to refuse access.

If you require help with your registration or have any questions you may contact Xtalks at: email: register@xtalks.com; phone: 416-977-6555, x 371.

By completing this registration form, you agree that the information you have provided is true and accurate.

(note: fields with marked "*" are required)